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Human blood plasma contains a plethora of proteins, encompassing not only proteins that have plasma-based functionalities, but
alsopossiblyeveryotherformoflowconcentratedhumanproteins.Asitcirculatesthroughthetissues,theplasmapicksupproteins
that are released from their origin due to physiological events such as tissue remodeling and cell death. Speciﬁc disease processes
or tumors are often characterized by plasma “signatures,” which may become obvious via changes in the plasma proteome proﬁle,
for example, through over expression of proteins. However, the wide dynamic range of proteins present in plasma makes their
analysisverychallenging, because high-abundance proteinstendtomaskthoseoflower abundance. Inthepresentstudy,weuseda
strategycombiningiTRAQasareagent which improvedthepeptideionizationandpeptideOFFGELfractionationthathasalready
been shown, in our previous research, to improve the proteome coverage of cellular extracts. Two prefractioning methods were
compared: immunodepletion and a bead-based library of combinatorial hexapeptide technology. Our data suggested that both
methods were complementary, with regard to the number of identiﬁed proteins. iTRAQ labelling, in association with OFFGEL
fractionation, allowed more than 300 diﬀerent proteins to be characterized from 400μg of plasma proteins.
1.Introduction
Blood circulates throughout every part of the body, and no
otherbioﬂuid hasthesamedegreeof intimacywiththebody.
Therefore, it is not surprising that it possesses such a wealth
of information concerning the overall pathophysiology of a
patient. As an example, alterations in protein abundance can
serve to indicate pathological abnormalities: diseases, toxic
eﬀects of clinical treatments and so forth.
The choice between plasma and serum has been abun-
dantly documented in the literature [1, 2]. When blood is
collected,manychangesoccurintheproteinsitcontains,due
to the presence of proteolytic enzymes (proteases) and other
enzymes, which remain active in the blood sample during
handling and processing. The HUPO Committee and its
research collaborators concluded with the recommendation
that plasma is the preferred specimen taken from the blood.
T h er e a s o n sf o rt h i sa r e( i )l e s se xv i v od e g r a d a t i o n ,a n d
(ii) much less variability than in the case of the protease-
rich process of clotting. Misek et al. [3] showed with Cy5-,
Cy3-, Cy2-labeled serum and plasma on DIGE-2D-PAGE,
after extensive fractionation of intact proteins before tryptic
digestion, that isoforms of abundant proteins were more
often shifted to lower-than-expected MW in serum than in
plasma. Tammen et al. [4] reported that 40% of the low-MW
peptides detected were serum speciﬁc.
Biomarker discovery in plasma is often limited by the
availability of suﬃcient volumes. It is also complicated by
the wide dynamic range of the human plasma proteome,
which comprises proteins spanning concentrations of more
than 11 orders of magnitude, with the top 10 most abundant
plasma proteins accounting for approximatively 90% of the
total plasma proteins. Potential disease biomarkers are often
present in low concentrations, and the dynamic range of
the plasma proteins poses a signiﬁcant analytical challenge
to proteomic approaches. A prefractionation method is2 Journal of Biomedicine and Biotechnology
necessary in the biomarker process. The most common
technique is immunodepletion, which has been extensively
used for the speciﬁc removal of high abundance proteins,
based on the action of speciﬁc antibodies [5, 6]. More
recently, saturation protein binding to a random pep-
tide library has been proposed as an alternative method
[7, 8].
One of the methods used to discover biomarkers is
the identiﬁcation and quantiﬁcation of proteins, based
on an iTRAQ quantitative proteomic approach. iTRAQ is
ideally suited for biomarker applications, as it provides both
quantiﬁcation and multiplexing in a single reagent, and has
beenappliedtotheanalysisofclinicalsamplessuchashuman
cerebrospinal ﬂuid, and disease tissues, and has been used
for the in vitro proﬁling of cells to identify diﬀerentially
expressed proteins. To the best of our knowledge, there
are currently only two published papers where iTRAQ has
been used to study human serum and plasma. Hergenroeder
et al. [9] employed iTRAQ and electrospray ionization
tandem mass spectrometry (ESI-MS/MS) to serum depleted
of 12 high abundance proteins, leading to the identiﬁcation
of 160 proteins. Song et al. [10] used iTRAQ protocol
and MALDI-MS/MS to identify 105 proteins in human
plasma.
We recently demonstrated that iTRAQ labelling and
peptideOFFGELfractionationinaﬁrstdimensionimproved
the identiﬁcation of weakly concentrated proteins from a
cellular extract [11]. The aim of the present study was ﬁrstly,
to use iTRAQ as reagent to improve the MALDI ionization
of peptides and secondly to evaluate the performance of
our previous strategy for the study of the human plasma
proteome, in terms of the number of identiﬁed proteins, the
presence of high abundance proteins, and the identiﬁcation
of medium and weakly concentrated proteins.
2.MaterialsandMethods
2.1. Human Blood Plasma Samples. A citrated plasma pool,
composed of a collection of 10 methylene blue virus-
inactivated plasma samples, obtained from healthy donors
using apheresis, was provided by the French National
Public Blood Institution (Etablissement Franc ¸ais du Sang
Bourgogne Franche Comt´ e, CHU Le Bocage, Dijon, France).
The plasma pool (Internal Quality Control) was loaded into
0.5ml bar-coded straws, stored at 4◦C for 2 hours, and then
transferred into liquid nitrogen. The plasma straws were
packed in a dry ice container during transportation to our
laboratory and were immediately stored in a −80
◦Cf r e e z e r
until they were needed.
2.2. Immunoaﬃnity Depletion of High-Abundance Proteins.
In a four independent experiments, the 14 most highly
abundant proteins were removed from the plasma, using
antibody-based depletion withaHuman14MultipleAﬃnity
Removal System, MARS-Hu 14 (Agilent Technologies, Santa
Clara, CA, USA). Two diﬀerent spin cartridges were used
to deplete 10 times 10μLo f0 . 2 2 μm-ﬁltered plasma. This
process required 2 buﬀers, A and B (Agilent Technologies).
The pH 7.4 phosphate salt-containing buﬀer A was used for
the equilibration, loading and washing steps. Flow-through
fractions containing low-abundance proteins were collected
a n ds t o r e da t−80
◦C until they were ready for analysis. A pH
2.5 urea buﬀer B was used for elution of the bound, highly
abundant proteins from the cartridge. The experiment was
conducted at room temperature according to the protocol
supplied by the manufacturer.
2.3. Hexapeptide Ligand Library Treatment. Plasma proteins
were “equalized” using the ProteoMiner Protein Enrichment
Kit(Bio-radlaboratories,Hercules,CA,USA).Fourdiﬀerent
spin columns were run in parallel, according to the manufac-
turer’s instructions. Each was loaded with 900μLo f0 . 2 2μm-
ﬁltered plasma, for 2 hours at room temperature, and with
100μL of 1M sodium citrate, and 20mM of HEPES, at
pH 7.4. No bead agglomeration was observed. The proteins
were desorbed using a two-step elution. The ﬁrst beads were
incubated twice with 100μL of the kit elution reagent (4M
urea, 1% (w/v) CHAPS, 5% (v/v) acetic acid) for 15 minutes.
Then, 100μL of 6M guanidine-HCl, at pH 6.0, were added
twice for 15 minutes. For each column, the four elution
f r a c t i o n sw e r ep o o l e da n ds t o r e da t−80
◦C, until they were
needed for analysis.
2.4. Buﬀer Exchange and Protein Content Estimation. Using
2000 MWCO Hydrosart Vivaspin 2 spin concentrators
(Sartorius Stedim Biotech, G¨ ottingen, Germany), the pre-
fractionated plasma samples were concentrated and buﬀer-
exchanged, by subjecting them to repeated (four times)
centrifugation, to an appropriate 0.5M triethylammonium
bicarbonate (TEAB) pH 8.5 buﬀer (Sigma-Aldrich Corpora-
tion, Saint Louis, MO, USA), for downstream analysis. The
protein concentrations of whole and prefractionated plasma
samples were determined using a FluoroProﬁle Protein
Quantiﬁcation Kit (Sigma-Aldrich Corporation), with BSA
as the standard.
2.5. 1-Dimensional Gel Electrophoresis (1DGE). Equal
amounts of proteins from crude and prefractionated plasma,
obtained by immunoaﬃnity depletion or hexapeptide ligand
library treatment, were diluted in an SDS loading buﬀer at
2mg/mL, and heated to 100
◦C for 10 minutes. The elution
beads from one ProteoMiner column were then washed and
directly boiled at 100
◦C for 10 minutes in a 100μLS D S
loading buﬀer. The proteins were then separated onto a
home-made 12.5% SDS-PAGE gel (16cm long and 1.5mm
thick), using a standard Laemmli buﬀer system in an SE
600 Ruby electrophoresis unit (GE Healthcare, Chalfont
Saint Giles, UK). Precision Plus Protein Standards (Bio-rad
laboratories) were loaded in the molecular weight marker
lane. The gel image was acquired on an Ettan DIGE Imager
(GE Healthcare), after total protein ﬂuorescent poststaining
with Deep Purple (excitation, 532nm; emission 610nm),
according to the standard protocol (GE Healthcare).
2.6.ProteinDigestionandPeptideiTRAQLabelling. 100μgo f
proteinsolutions,at5mg/mLin0.5MTEAB,atpH8.5,wereJournal of Biomedicine and Biotechnology 3
4 human blood plasma aliquots
Prefractionation
Protein trypsic digestion
Peptide iTRAQ labelling
Pool: 400μg proteins
Peptide OFFGEL 24 fractionation
Nano RPLC-MALDI MS/MS
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Figure 1: Illustration of the workﬂow.
reduced for 1 hour at 60
◦C with 5mM tris-(2-carboxyethyl)
phosphine (TCEP) and were cysteine-blocked with 10mM
methyl methanethiosulfonate (MMTS) at room temperature
for 10 minutes. The proteins were then digested for 40
hours at 37
◦C, by 10μg of TPCK-treated trypsin, with CaCl2
(Applied Biosystems, Foster City, CA, USA). Each peptide
solution was labelled for 3 hours at room temperature,
using an iTRAQ reagent previously reconstituted in 70μL
of ethanol, according to the iTRAQ Reagents Multiplex Kit
protocol (Applied Biosystems). The reaction was stopped by
adding milliQ water, and the samples labelled, respectively,
with 114, 115, 116, and 117 mass-tagged iTRAQ reagents
were combined according to the experimental protocol
shown in Figure 1.
2.7. Peptide OFFGEL-IEF Fractionation. For pI-based pep-
tide separation, the 3100 OFFGEL Fractionator (Agilent
Technologies) was used with a 24-well setup. Prior to
electrofocusing, the peptide samples were desalted onto a
Sep-Pak C18 cartridge (Waters Corporation, Milford, MA,
USA) and were resolubilized in 3.6mL of 5% (v/v) glycerol
and 1% (v/v) IPG buﬀer, at pH 3–10 (GE Healthcare). The
24cm-longIPGgelstrips(GEHealthcare),witha3–10linear
pH range, were rehydrated for 15 minutes according to the
manufacturer’s manual. Then, 150μL of sample was loaded
in each of the 24 wells.
Electrofocusing of the peptides was performed at 20
◦C
until a level of 50kVh was reached. After focusing, the 24
peptide fractions were withdrawn and the wells were rinsed
with 200μL of a solution of milliQ water/methanol/formic
acid(49/50/1).After15minutes,eachoftherinsingsolutions
was pooled with its corresponding peptide fraction. All
of the fractions were evaporated by centrifugation under
vacuum and were maintained at −20
◦C. Just prior to nano-
LC separation, the fractions were resuspended in 20μLo f
milliQ water with 0.1% (v/v) TFA.
2.8. Nano-LC Separation. The peptide fractions were sep-
arated on an Ultimate 3000 nano-LC system (Dionex
Corporation, Sunnyvalle, CA, USA), using a C18 column
(PepMap100, 3μm, 100A, 75μmi d×15cm, Dionex Corpo-
r a t i o n )a taﬂ o wr a t eo f3 0 0n L / m i n u t e .B u ﬀer A comprised
2% ACN in milliQ water, with 0.05% TFA, and buﬀer B
comprised 80% ACN in milliQ water, with 0.04% TFA.
The peptide solutions were ﬁrst desalted for 3 minutes
using buﬀer A only on the precolumn, and the separation
occurred over a period of 70 minutes, with the following
gradient: 0 to 20% B in 10 minutes, 20% to 55% B in 55
minutes, and 55% to 100% B in 5 minutes. Chromatograms
were recorded at a wavelength of 214nm. Following a
12-minute run, the peptide fractions were collected for
10seconds using a Probot microfraction collector (Dionex
Corporation), and spotted directly onto a MALDI sample
plate (1664 spots per plate, Applied Biosystems). The CHCA
matrix (LaserBioLabs, Sophia-Antipolis, France), with a
concentration of 2mg/mL in 70% ACN, in milliQ water with
0.1%TFA,wascontinuouslyaddedtothecolumneﬄuentvia
a micro “T” mixing piece at a ﬂow rate of 1.2μL/min.
2.9. MALDI-MS/MS. MS and MS/MS analyses of oﬄine
spotted peptide samples were performed using the 4800
MALDI-TOF/TOF Analyser (Applied Biosystems). After
screening of all LC-MALDI sample positions in MS-positive
reﬂector mode, using 1500 laser shots, the fragmentation
of automatically selected precursors was performed at a
collisionenergyof1kVusingairasthecollisiongas(pressure
∼2 ×10
−6 Torr). MS spectra were acquired between m/z
800 and 4000. The parent ion of the Glu-1 ﬁbrinopeptide
at m/z 1570.677, diluted in the matrix (3 femtomoles per
spot), was used for internal calibration. Up to 12 of the
most intense ion signals per spot position, characterised by
an S/N > 12, were selected as precursors for MS/MS acqui-
sition. Peptide and protein identiﬁcations were performed
using ProteinPilot Software v 2.0 (Applied Biosystems) and
the Paragon algorithm [12]. Each MS/MS spectrum was
searched against the Uniprot/Swissprot database (release
96, September 2008) for Homo Sapiens species, with the
ﬁxed modiﬁcation of methyl methanethiosulfonate-labelled
cysteine parameter enabled. Other parameters such as the
tryptic cleavage speciﬁcity, the precursor ion mass accuracy
and the fragment ion mass accuracy, are MALDI 4800 built-
in functions of the ProteinPilot software. The ProteinPilot
software calculated a conﬁdence percentage (the unused
score), which reﬂects the probability of a hit being a “false
positive,” meaning that at the 95% conﬁdence level, there
is a false positive identiﬁcation probability of about 5%.
While this software automatically accepts all peptides with
an identiﬁcation conﬁdence level > 1%, only proteins having
at least one peptide above the 95% conﬁdence level were4 Journal of Biomedicine and Biotechnology
initially recorded. Low conﬁdence peptides cannot give a
positiveproteinidentiﬁcationbythemselvesbutmaysupport
the presence of a protein identiﬁed using other peptides with
higher conﬁdence. Searches against a concatenated database
containing both forward and reversed sequences enabled the
false discovery rate to be kept below 1%.
2.10. Data Analysis. In order to analyse the quality of pI
fractionationafterOFFGEL-IEFandMALDI-MS/MSidenti-
ﬁcation, the experimental pI was calculated for each peptide,
using the pI/MW tool of the ExPASy Proteomic Server [13]
checking all the deamidation modiﬁcations which could
inﬂuence its value. Then, the average experimental pI of
peptides (after ﬁltering for false positive responses) was
compared, for each of the 24 fractions, with the theoretical
pH values provided by Agilent Technologies for 24 cm-
long IPG gel strips with a 3–10 linear pH range. To
study the relative abundance of proteins in the plasma,
the MS/MS spectra, which enabled protein identiﬁcation
with at least 2 peptides, were counted for each protein
[14].
3. Results andDiscussion
Our strategy for the study of the human plasma proteome
was based on three-step fractionation. In the ﬁrst step, the
plasmasampleswereprefractionatedusingeitheranimmun-
odepletion method, or a peptide ligand library strategy. The
proteinswerethendigestedbytrypsin,resultedpeptideswere
iTRAQ-labelled and OFFGEL-fractionated in 24 fractions.
Each fraction was then analysed by nano-LC on a C18
column (Figure 1).
3.1. Identiﬁcation of Proteins. The experimental design for
the iTRAQ labeling of proteins from the immunodepleted
and bead-treated plasma was the same. The prefractionated
plasma samples were concentrated and dissolved in the
appropriate iTRAQ buﬀer using spin concentrators before
the steps of reduction, MMTS blocking, digestion and
iTRAQ labelling (Figure 1). After OFFGEL separation of
400μg of iTRAQ-labelled peptides in 24 fractions, Protein
Pilot software leads to the identiﬁcation of 332 proteins
in immunodepleted plasma and 320 proteins from the
hexapeptide ligand library treated plasma (Figure 2).
The average experimental pH value of each OFFGEL
fraction is indicated by a bar in Figure 3. The theoretical
pH values provided by the manufacturer are also shown by
a dashed line. The pI value for each identiﬁed peptide was
calculated using Bjellqvist’s algorithm [15], without taking
the iTRAQ groups in the N-term position, and/or the lateral
lysine chain, into account. Using these data, average pI
values with standard deviations were calculated for all of the
peptides identiﬁed in each fraction (Figure 3). The average
experimental pI value deviated from the theoretical pI value
by an average error of ±0.90, for both prefractionation
strategies. From the immunodepleted plasma, 243 proteins
werecharacterizedbyatleast2peptides,andfromtheplasma
treated by the hexapeptide bead library, 228 were associated
70
(162) 158 85
(174)
IM
PM
Figure 2: Venn diagram presenting the number of total plasma
proteins identiﬁed with two or more peptides (in brackets, with
one peptide) after immunoaﬃnity depletion of high-abundant
proteins (IM), hexapeptide ligand library treatment (PM) or both
prefractionation methods.
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Figure 3: Analysis of the quality of the OFFGEL fractionation
of iTRAQ-labelled peptides from immunoaﬃnity depleted (IM)
or hexapeptide ligand library treated (PM) plasma. The average
experimental pI of all peptides in each of the 24 OFFGEL fractions
after ﬁltering for false positive is presented as bars. Error bars
indicate the SD of each fraction’s experimental pI. The broken line
is based on the theoretical pI values for an IPG strip of 24cm, pH
3–10 provided by Agilent Technologies.
with at least 2 peptides, suggesting that both prefractioning
methods produced virtually the same number of identiﬁed
proteins.
Among these, 158 were common to both methods
(Figure 2). Nevertheless, in addition to these mutual pro-
teins, 85 proteins (with at least 2 peptides) were identiﬁed
by immunodepletion technology only, and 70 proteins (with
at least 2 peptides) were identiﬁed by the equalizer strategy
only, suggesting that these strategies are complementary. The
merging of both sets of data allowed a total of 313 proteins
with at least 2 peptides to be identiﬁed.Journal of Biomedicine and Biotechnology 5
Table 1: Protein recovery after plasma prefractionation using immunoaﬃnity depletion of high-abundant proteins or hexapeptide ligand
library treatment. Protein content was estimated using FluoroProﬁle Protein Quantiﬁcation Kit.
MARS-Hu 14 Proteo Miner
Plasma volume loaded (μL) 10 × 10 depletion cycles 900
Protein quantity loaded (mg) (whole plasma : 63mg/mL proteins) 6,3 56,7
Protein quantity recovered after prefractionation (μg) 340 401 415 299 1420 1158 1195 1572
Average protein quantity recovered after prefractionation (μg) 364 (or 36.4μg per depletion cycle) 1336
% of total protein mass removal by prefractionation 94.2 97.6
Ap r e v i o u ss t u d yc o n d u c t e db yu sw i t h4 0 0 μgo f
immunodepleted plasma and treated in the same con-
ditions, except iTRAQ labelling, showed 115 identi-
ﬁed proteins (Supplementary Material available online at
doi:10.1155/2010/927917) in agreement with Song et al.
results [10]. This result demonstrated the eﬃciency of
iTRAQ labelling for the peptide ionization and the protein
identiﬁcation according our previous study [11].
3.2. Evaluation of the First Prefractioning Step. The human
plasma was prefractionated using two diﬀerent methods: an
immunodepletion strategy on a human MARS-14, which
depleted the 14 most abundant plasma proteins, and
a peptide ligand library technology with a ProteoMiner
column, which should “equalize” the plasma proteins.
The reproducibility of these approaches was evaluated by
four independent experiments (Figure 1). The total protein
content was used to investigate reproducibility and pro-
tein recovery (Table 1). The total protein concentration of
untreated plasma was 63mg/mL. The mean recovery rate
of the eluted bead-treated plasma was 2.4% (in agreement
with previous results [8]), compared with 5.8% following
the depletion process using the MARS-14 column. Both
methodologies showed a reproducibility of around 15%, in
the determination of total protein content.
For each approach, reproducibility of biological experi-
mentandiTRAQlabellingwereevaluatedwiththecoeﬃcient
variation calculation from ProteinPilot results. An average
of ±18% variation across the 4 experiments with the
human MARS-14 strategy and an average of ±11% with the
ProteoMiner approach were exhibited. Separation of native
plasma, immunodepleted, and bead-treated plasma samples
bySDS-PAGErevealedasigniﬁcantreductioninthedynamic
range of protein concentration in the treated fractions, when
compared with native plasma (Figure 4) but did not identify
one prefractionation method as being superior to the other.
Comparison of the 20 most abundant proteins evaluated
by the MS/MS spectra counting technique indicated that
both prefractioning methods were equivalent, in terms
of the estimated protein concentrations (Figure 5). With
ProteoMiner treatment, ﬁbrinogen alpha and beta chains
were the most commonly found proteins, thus suggesting
thatthistechniquecouldbemoresuitableforserumsamples.
3.3. Gene Ontology Annotations. Gene ontology analysis
for cellular localization revealed that a large proportion
15
20
25
37
50
75
100
150
250
MW
(kDa) 1 2 3 4
MW
(kDa)
Figure 4: 1DGE analysis of human blood plasma before and after
prefractionation using immunoaﬃnity depletion of high-abundant
proteins or hexapeptide ligand library treatment. An equal amount
of proteins from whole plasma (lane 1), plasma fraction from
MARS-Hu 14 (lane 2), plasma fraction from ProteoMiner (lane
3), and potentially remaining proteins from boiled in SDS loading
buﬀer ProteoMiner beads after elution (lane 4) were separated on
12.5% SDS-PAGE gel and were stained with Deep Purple.
of proteins, with predicted extracellular locations (33%)
(Figure 6(b)) was present in our plasma proteome map.
Functional classiﬁcation also revealed that most of the
proteins are involved in “binding” and enzyme activities
(Figure 6(a)).
Among these proteins, we identiﬁed medium con-
centrated proteins with concentrations ranging around
30ng/mL, such as P-selectin, cadherin 5 [16, 17]( Table 2).
We successfully detected the low-concentrated proteins Hep-
atocyte growth factor activator, insulin like growth factor
binding-protein2 and Sex hormone-binding globulin in
the both experiments with ProteinPilot unused score >2
(proteinsidentiﬁedwithatleast2peptides;95%conﬁdence).
The literature data showed that the concentration of these
proteins was in the range of 8–18ng/mL [16, 18, 19].
Compared with the concentration of the most abundant6 Journal of Biomedicine and Biotechnology
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Figure 5: Relative abundance of the twenty most abundant proteins determined by counting the number of MS/MS spectra for each protein
identiﬁed after immunoaﬃnity depletion (IM) or Hexapeptide ligand library treatment (PM) of plasma.
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Figure 6: Pie charts showing the gene ontology classiﬁcation of identiﬁed plasma proteins according to cellular function (a) and to cellular
component category (b).
plasma protein (HSA) which is around 50mg·mL, we can
conclude that the dynamic range to detect low-abundant
plasma proteins could be extended to 106-107.
4. Conclusions
The number of proteins which could be identiﬁed in 400μg
of plasma proteins was markedly increased in this study,
when compared to similar samples studied without iTRAQ
labelling, or with iTRAQ labelling, but without OFFGEL
fractionation [10], suggesting that our strategy improved the
proteome coverage of human plasma.
The limited number of individual proteins identiﬁed in
this study, despite prefractionation, highlights the challenge
of plasma-based biomarker discovery. From our experience,
similariTRAQanalysesofcellularextractsareabletoidentifyJournal of Biomedicine and Biotechnology 7
Table 2: Some of the weakly abundant plasma proteins identiﬁed with two or more peptides after immunoaﬃnity depletion of high-
abundant proteins (IM) or hexapeptide ligand library treatment (PM). Associated concentrations were found in the literature in the mid-
range from 5 to 50 000 ng/mL serum or plasma.
Protein name Prefractionation Concentration Bibliographic reference
Plasma retinol-binding protein PM 44.4μg/mL (plasma) [20]
IM
Kallistatin IM 22.1μg/mL (plasma) [21]
Ficolin-3 IM 21.6μg/mL (plasma) [22]
Tetranectin IM 13.75μg/mL (serum) [23]
Selenoprotein P IM 5.3μg/mL (plasma) [24]
Von Willebrand factor PM 1.3μg/mL (plasma) [16]
IM
Intelectin-1 PM 0.1 to 1.0μg/mL (serum) [25]
Extracellular SOD PM 150ng/mL (plasma) [26]
IM
Mannose-binding lectin (Protein C) IM 97ng/mL (plasma) [16]
Insulin-like growth factor binding protein 3 PM 59ng/mL (plasma) [16]
IM
P-selectin IM 30ng/mL (plasma) [17]
Cadherin 5 PM 30ng/mL (plasma) [16]
IM
Macrophage colony-stimulating factor 1 receptor (M-CSF R) IM 26ng/mL (plasma) [16]
Hepatocyte growth factor activator PM 17.6ng/mL (serum) [18]
IM
Insulin-like growth factor binding protein 2 PM 15ng/mL (plasma) [16]
IM
Sex hormone-binding globulin PM to 8.1ng/mL (plasma) [19]
IM
more than 1000 diﬀerent proteins [11]. Clearly, the presence
of many highly abundant proteins in human plasma and
therefore,aftertrypsindigestion,thepresenceofmanyhighly
concentrated peptides prevent a good MALDI ionization of
weak-concentrated peptides and therefore limit the depth of
analysis. Theses results argue in favour of the search for new
strategies for the removal of abundant plasma proteins [27],
or for the enrichment of less abundant proteins, in order to
facilitate the eﬃcient discovery of biomarkers.
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